GHRP-2GH Secretagogue PeptideSafety Rating 7/10

TypeSynthetic hexapeptide GH secretagogue
CAS158861-67-7
MW817.97 g/mol
AAs6
Primary research areaGrowth hormone secretagogue research

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range1–2 mcg/kg IV tested; research use commonly 100–300 mcg/injectionsource ↗
AdministrationSubcutaneous injection
Half-life~15–60 minutes
Safety7/10 · Not FDA-approved
NCAA D1Banned

Price Comparison

Compare vendors · per 10mg

11 vendors competing

VendorPrice$ / mgUpdated
Core PeptidesBest $/mgCOA ✓ · 3P$29.00$2.90Apr 16, 2026Buy →
SomaChemsCOA ✓ · 3P$15.99$19.99−20% · code PEPTIDEPRICES$3.20May 14, 2026Buy →
Swiss ChemsCOA ✓ · 3P$179.95$3.60Apr 17, 2026Buy →
$25 off $100+·auto
Swiss ChemsCOA ✓ · 3P$19.95$3.99Apr 17, 2026Buy →
$25 off $100+·auto
Guru PeptidesCOA unknown$19.99$4.00May 16, 2026Buy →

Overview

About GHRP-2

Mechanism of action

Synthetic hexapeptide; binds GHS-R1a (ghrelin receptor); stimulates GH release with some GHRH-independent activity; also elevates cortisol, prolactin, and ACTH.

Safety profile

Hunger/appetite increase, water retention, cortisol and prolactin elevation, fatigue, tingling. More side effects than Ipamorelin. · Human clinical data available; increases cortisol/prolactin modestly; hunger stimulation; well-tolerated

Storage

Stability & handling

❄️Lyophilized (powder)−20°Clong-term stable
💉Reconstituted2–8°Cwithin 30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on GHRP-2

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • GHRP-2 (pralmorelin/KP-102) is approximately 10-fold more potent than GHRP-6 in stimulating GH secretion, with pharmacological studies (Doi et al., 2004) demonstrating superior resistance to somatostatin suppression compared to GHRH — allowing robust GH release even in states of elevated somatostatin tone.
  • In a controlled study in healthy men (Laferrère et al., JCEM 2005), subcutaneous GHRP-2 infusion increased food intake by 35.9% above saline control, confirming its orexigenic activity via ghrelin receptor activation — a property that distinguishes it from more selective GH secretagogues and relevant for cachexia applications.

7 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch